SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " pharma " 696 found 🔀 AI-powered Shuffle
SpyGlass Pharma Acquires Advanced Vision Science, Securing Commercial IOL Supply, Accelerating Lens Portfolio Expansion
IRVINE, Calif.—SpyGlass Pharma, Inc. (Nasdaq: SGP), a late-stage biopharmaceutical company focused on transforming treatment paradigms for patients with chronic eye conditions, has announced the acquisition of all the outstanding shares of common stock of Advanced Vision Science, Inc. (AVS), an ophthalmic medical device company and manufacturer of intraocular lenses (IOLs) and lens materials, for approximately $13 million in cash. This acquisition secures scalable commercial IOL supply and accelerates lens portfolio expansion capability for SpyGlass Pharma, the announcement noted.
Wilson Sonsini Advises SpyGlass Pharma on Acquisition of Advanced Vision Science
On October 1, 2026, SpyGlass Pharma, a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions, announced the acquisition…
Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion
The portfolio comprises more than 15 proprietary brands and product lines and 10 branded generics across five product categories, sold in more than 40 countries through pharmacies, hospitals, retail chains and e-commerce. It is manufactured at GMP-certified facilities in Europe and the United States and supported by the Company's services in contract manufacturing, pharmaceutical distribution, telehealth and research and development.
Midtown Costco set to close, reopen as business center
Costco has committed to keeping the Midtown pharmacy open during the conversion.
Cardinal Health Extends CVS Health Pharmaceutical Distribution Agreement Through 2032
Cardinal Health (NYSE:CAH) has entered into a binding letter of intent to extend its pharmaceutical distribution agreement with CVS Health through June 30, 2032. The extended agreement will maintain the existing scope of distribution services provided by Cardinal Health to CVS Health.
Xtalks Announces its Life Science Webinar Calendar for October 2026
Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!
Xtalks Announces its Life Science Webinar Calendar for October 2026
/PRNewswire/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries....
September Monthly Review: Health MCP Guy?
For all the time I spend talking about APIs and data exchange, this newsletter has had embarrassingly little interoperability of its own. It’s old-school SaaS, baby - UI or bust. Not all of that is my fault! Substack, for all its popularity, is (as mentioned before) really frustrating as my system of record. The primary user it optimizes towards is the reader, whose attention feeds the app, the Notes feed, and the recommendation network that Substack is actually selling. Health API Guy is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Subscribe They’re falling into the same trap that Medium once sprinted into, albeit at a much more glacial speed. Younger generations may not remember (or never knew) it, but Medium once lured publications like The Ringer and Signal v. Noise onto its platform, only to lose them as it rebuilt itself around a paywall and an algorithmic feed. Substack’s original pitch circa 2020 was the antidote (you own your list), but every new feed feature chips away at it. I get it: writers are generic supply in the eyes of the Substack product team. Generic supply follows demand, so the consistent pressure on the PMs is to generate demand, which leads to every product cycle going toward discovery (Notes, recommendations, the app, live video). The end result lackluster author tools (laggy and broken analytics are truly crippling) all despite the premium price point. The archive is where it crosses from authorial gripes to actual reader impact, though. Across Substack and LinkedIn, I’ve published 1,218 posts and nearly 900,000 words since 2018. Substack’s native search can see only the 464 posts that live on Substack, and even there it’s woefully inadequate at surfacing relevant content (even for the guy who wrote it)! Readers have the same problem, writ large. Ask the Archive Fixing search (for both my readers and my own use) turned out to be extremely non-trivial, unfortunately: There’s no public API for readers to access content RSS exists for new content notification, but it only carries the 20 most recent posts and cuts paid ones off at the preview The only Substack MCP is an admin tool for analytics The export exists for authors, but it’s painfully awkward and slow. So I built something to work around that: the Health API Guy MCP. It’s a private MCP server holding the full text of everything I’ve written across Substack and LinkedIn. Add it to Claude or ChatGPT as a connector and you can ask things like: It pairs keyword search (for acronyms and case names, of which we have many) with semantic search. Every post is also labeled by topic, form, and court case, so you can pull a lawsuit’s (or multiple cases’) entire docket across Substack and LinkedIn in one query: Hail, Healthapiguyhydra This is also a bit of me eating my own cooking. I’ve spent the year arguing that headless healthcare is arriving and that developers want primitives over abstractions. Last week in Hail, Benihydra, I watched Salesforce plug its platform into Claude and bet that the records underneath outlive whatever interface sits on top: Salesforce must believe that the Hydra’s immortal head is the records, permissions, and business logic (in that they will survive whatever happens to the interface). It felt a bit hypocritical to keep my own archive behind a Substack search bar. The archive is the body. Substack is one head, and now whatever tool you might use is another. Will the EHRs follow my lead? Probably not imminently, but one can hope! Why Founding Members Only The MCP is available to Founding Member subscribers. A few reasons: It costs money and time to run. Hosting, the database, Clerk usage and AI compute for search and labeling are significant operational costs (that increase with usage). Substack gives me no way to automate access. There’s no API to check whether someone is a paid subscriber, so every user is manual operations for now. It’s a beta. We’ll need to improve things and parts will break. I’d rather they break for a small group of dedicated readers who will tell me about it. The Founding tier deserved a real benefit. Until now it was mostly a generous tip. Now it comes with something. If you’re already a Founding Member, reply to this email with the address you’d like provisioned. If you’re not and want in, upgrade here. Larger teams (such as companies) can get access too: group subscriptions at the Founding tier come with the group discount. The admin for the subscription can reply with the list of addresses to provision. Get 20% off a group subscription Pricing Founding membership is now a flat $200 a year, replacing the old suggested $150 that readers could adjust. Existing Founding Members will have access grandfathered in at their previous rate. Month in Review Articles Published Make Networks Dumb Again (Sep 11): AI is making old analog networks cheaper to use and flooding them with machine traffic in the process. A plea for agent-native rails with the intelligence at the endpoints, and for Washington to drag them to ubiquity. Interoperability, Unbuttoned (Sep 29): Interoperability is a series of workflows in a trenchcoat, and this post finally takes the trenchcoat off. A color-coded map shows which provider workflows went digital, which are fragmented, and which still run on fax. Video Content Antitrust’s System of Record Problem (Sep 3): The FTC’s investigation into Epic prompted a ninety-minute webinar, now posted with chapters and a smoothed transcript. We get into why market definition, missing B2B share data, and the SSNIP test leave antitrust poorly suited to systems of record, plus why information blocking may be doing more than any pending lawsuit. The Information Exchange: Cerner Milking Edition (Sep 18): This was so fucking fun. Ryan Tucker, Ryan Brickner, Brad Thorson, and I try an Around the Horn format, complete with points, penalties, and a mute button. We debate whether Oracle Health is dead, who would actually buy Cerner (IBM enters the chat), p(Doom), and why the front desk still hands you a clipboard. Regulatory Ask Not What Your Network Can Do (Sep 23): CDC’s RFI on public health data intermediaries lists use cases already served, unevenly, by eCR, lab reporting, IZ Gateway, and syndromic surveillance. The real opportunity sits in one question about AI: a network that can handle the next emergency without another interface project. Court cases Particle v. Epic: The Naughty Schoolteacher (Sep 4): After a summer-long vigil, the answer on Epic’s early summary judgment bid is two paragraphs and a remedial assignment. Particle advances to the next grade, and market definition gets another year of discovery. The Epic Discovery Files (Sep 8): Texas’s motions to compel arrive with a 251-page appendix of requests, objections, and meet-and-confer letters with Cravath. Inside: Epic using generative AI for document review, denied interoperability requests in scope, and Noerr-Pennington raised against lobbying discovery. Epic v. Health Gorilla: “Working as Designed” (Sep 9): Epic wants nothing to do with the data breach MDL, and explaining why puts fresh discovery on the public docket. The spiciest allegation: Health Gorilla told GuardDog to scrub its law firm business from its website instead of cutting off access. Veeva v. Epic: Legal Bypass Surgery (Sep 15): Veeva asks the Wisconsin Supreme Court to skip the Court of Appeals, while law professors and three policy groups line up as amici. Meanwhile, Epic’s lawyers apologize for another round of citation errors, including a quote that never existed. Texas v. Epic: Behind the Black Bars (Sep 17): The court portal served up Epic’s unredacted filings, revealing a $5 million document review budget and the AI workflow behind it. Also inside: the 200-plus company names Texas wants searched, and one very expensive Zoom invitation. OpenEvidence v. Doximity: Consequences Will Follow (Sep 25): OpenEvidence tells the court it will not comply with a discovery order, and its own lawyers at Quinn Emanuel say they won’t defend the choice. Add years of Slack reported unrecoverable, and Rule 37 sanctions come into view. Health Tech Keeps Choosing Violence (Sep 28): Doximity moves to end OpenEvidence’s case, Epic asks Texas to show its work, and a sleepy Audacious Inquiry patent fight sprouts antitrust and information blocking counterclaims. The main event is a long-sealed Cognizant v. Infosys ruling that hints where system of record antitrust claims can survive. EHRs One Verb for Oracle Health (Sep 14): Oracle’s earnings call quantifies every data center to the decimal point, while Oracle Health gets a single verb: “accelerate.” Panning the few healthcare mentions turns up an agentic care management system, a research-to-care ledger play, and the question of whether healthcare gets Larry’s patience. Epic’s Forretress Under Siege (Sep 30): Judy Faulkner tells a panel Epic paused hundreds of projects to harden its software and calls it a “shame,” while a spokesperson insists the roadmap hasn’t changed. Project Glasswing, a Pokémon-branded QAN sprint, and a trove of Jodel grievances reconcile the two Epics and preview the Jevons paradox coming for all software. Industry Analysis Scanning for a Network (Sep 1): Scan.com raises $220M to build the imaging network labs never got, speedrunning Zocdoc’s consumer-to-B2B pivot. Its wedge to network density may be the most American one available: personal injury litigation. The Front Desk Wants the Damn Whole Building (Sep 16): Hello Patient buys Converse Health, pushing its AI front desk into referrals, chart work, and prior auth. The copilot categories keep blurring, and your distribution partner is still your final boss. Cross-industry Comparisons A Different Patchwork Quilt (Sep 10): Healthcare loves to envy open banking, but the US version has no mandate, a toll booth at Chase, and data quality problems of its own. The grass isn’t greener; it’s another American patchwork quilt, and perhaps a worse one. Hail, Benihydra (Sep 21): Salesforce brings its platform into Claude, Slack, and its own agent, inviting the interfaces that might replace it. Cut off one head and more grow back, so long as the records underneath stay put. Living on A Trade Secret Prayer (Sep 22): Six credit unions are suing Fiserv, the Epic of core banking, by claiming their own member records as trade secrets. Banking has no Cures Act, so its lawyers reach for legal alchemy that healthcare has already tried. Other News None this month External Media Nabla Accelerate NYC: I kicked off fall conference season at Nabla’s Accelerate event in New York, where Delphine Groll opened by asking the room to picture the company it wants to become and the one it doesn’t. I liked her framework of bureaucracy, fear, and ego as the blockers. I also love vendor conferences/events in general - different vibe than industry biggies. Healthcare 101 with Nikhil Krishnan: I briefly guest lectured Out-Of-Pocket’s Healthcare 101 class. Appreciated Nikhil’s takeaways cover whether AI doctors can query HIEs, why healthcare’s data-liberation rules beat most industries’, and the hi-res graphic is in the comments. HCN: Epic Probed by the FTC: I joined the HCN guys to talk through the FTC’s investigation into Epic. Cedric’s new hairdo was an unexpected plot twist. The episode also covers MFN drug pricing, healthcare M&A and Eli Lilly’s acquisition streak. Fall Conferences: At eHealth Exchange’s Annual Meeting in Austin on Oct 27, I’ll moderate a panel on the tensions between AI, HIEs, and timely patient access with Jean Ross (Primary Record), Therasa Bell (Kno2), Byron Crowe (Doctronic), and Michael Marchant (Freenome). Here’s the rest of my schedule if you want to meet up: CommonWell (Redwood Shores, CA): Oct 13-14 Will be participating in a fun Jeopardy event Open@Epic (Madison, WI): Oct 20-23 Will be enjoying Verona, Willy Street, and other local adventures eHealth Exchange and Sequoia Project (Austin, TX): Oct 27-29 Yeehaw HLTH (Vegas): Nov 15-18 Groundhog Day, Venetian Edition RSNA (Chicago): Nov 30-Dec 2 See me at “Governing AI in Breast Imaging: What Health Systems Are Actually Doing” Digital Health Counsel 2026 AI Summit (Seattle): December 2-3 Will likely be speaking to a bunch of lawyers about information blocking Posts I Liked ChatGPT’s Epic integration: game changer or nothing burger?: Joshua Liu, MD offers five thoughts on OpenAI’s Epic launch, starting from the point that it rides the same open APIs available to anyone. He argues read-only access leaves ordering to Art and the ambient startups, and asks why HCA is piloting it alongside Commure. He’s sorta a must-follow at this point - consistently excellent, thought-provoking takes. Epic, Lilly, and the Discovery pass: Seth Chaney reads Epic’s first major Discovery deal (with Eli Lilly), as well as its revised developer terms on commercial displays, as the pipe finally opening between EHRs and pharma. Life sciences and health continue to collide. Scott Rossignol on EHR payer platforms and ePA fees: Scott argues the top ambulatory EHR vendors are turning the prior auth mandate into a per-member-per-year toll on payers, for an API whose operating cost has nothing to do with covered lives. His fix is two lines of regulatory text: put the CRD/DTR/PAS certification criteria in the Base EHR definition, and bring payer-facing ePA connectivity under § 170.404’s cost-based fee rules. It’s a good solution. Health API Guy is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Subscribe
AAPS PharmSci 360 Offers Fresh Insights for Industry Scientists
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.
Minaris Adds Dedicated Viral Vector Business Unit
Minaris is adding a dedicated viral vectors business unit, redefining its business model around that, cell therapies, and advanced testing.
What Does Anthropic’s Wet Lab Mean for Pharma?
Anthropic has established a wet lab in the San Francisco East Bay. In this article, experts explore what this means for scientific oversight, data ownership, and AI’s potential to transform drug discovery and rare disease research.
OBIO marks $1bn funding milestone for Canadian health tech ventures
Life sciences and technology companies supported by the OBIO's CAAP have collectively raised more than $1bn in capital.
Light-driven nickel catalyst forms chemical bonds using less metal
Pharmaceuticals, fine chemicals, and agrochemicals are produced industrially using a wide range of chemical reactions. These processes need to become more efficient, less expensive, and more sustainable.
Dealroom.co | Earth Science Tech buys California pharmacy, expands to 34 US jurisdictions
What's the deal? Earth Science Tech (OTC: ETST) has acquired Med…
Domino Data Lab and EPAM Partner to Accelerate AI Adoption in Life Sciences
Combines Domino’s enterprise platform with EPAM’s global engineering to scale compliant AI applications and advanced analytics across global biopharma SAN FRANCISCO, Sept. 29, 2026 — Domino Data Lab, provider of the unified platform to build, scale, and govern enterprise AI solutions for the most consequential industries, today announced a strategic partnership with EPAM, a leading […]
Where Healthcare Knows Your Name
See how two Health Mart pharmacies connect patients to medications, services and personalized support while helping keep care close to home.
FTSE 100 rises as AstraZeneca lifts healthcare sector
London's FTSE 100 rose on Tuesday, lifted by pharmaceutical stocks after AstraZeneca agreed to take a $2 billion stake in Summit Therapeutics to advance cancer research.
1 in 7 Science Institute Dropouts Enter Medical Fields
1 in 7 Science Institute Dropouts Enter Medical Fields 418 of 2,939 dropouts from 2021-2026 advanced to medical/pharmaceutical sectors; lawmaker urges curriculum review
Opioid settlement funds could bridge some health gaps
Back when now-Gov. Maura Healey was the Massachusetts attorney general, in July 2021, she sued opioid distributors, manufacturers, and pharmacies for their prescription practices, which the state argued contributed to a national opioid crisis. What resulted was a settlement of more than $1 billion from opioid-makers Johnson and Johnson and opioid-distributors McKesson, Cardinal, and AmerisourceBergen. […]
Why This Regeneron Rival Just Skyrocketed 90%
Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' Eylea.
How a UTC professor is helping first-year chemical engineering students explore career paths
What does a chemical engineer do? How can a student prepare for medical or pharmacy school? Where can students find people and resources to help answer those questions? Dr. Bradley Harris, head of UTC’s Department of Civil and Chemical Engineering in the College of Engineering and Computer Science (CECS), is helping students begin those conversations through A Moc’s First Year, a campuswide program designed to help incoming first-time, full-time undergraduates make connections to UTC, Chattanooga and one another.
Republicans and Democrats Find a Unifying Target: Pharmacy Benefit Managers
Some states have considered barring companies that own a PBM from also owning brick-and-mortar pharmacies, as CVS does. Two states have followed through. A similar proposal at the federal level has gained prominent sponsors, aligning conservative, business-friendly Republicans with Democrats traditionally more open to government regulation.
CPHI Milan 2026: Clinical data drives hair, mood, heart & cognitive health ingredients
Customers are increasingly opting for human data over hype. In this space, CPHI Milan 2026 will convene pharmaceutical and nutraceutical players who are
Flu shots now available for the UK campus community
UK students, employees and community members can now schedule their seasonal flu shots at convenient campus locations.
The New Health Care Populism
Fear over rising costs is fueling bipartisan motivation to confront drug companies, insurers, and pharmacy benefit managers directly, with candidates on both sides racing to appear stronger on those areas than their opponents rather than litigating the Affordable Care Act. Republicans have been espe
BrightSpring Health Targets Growth Through Specialty Pharmacy, M&A and AI
BrightSpring Health Services (NASDAQ:BTSG) outlined its growth strategy across pharmacy and provider services at the Bernstein healthcare services conference, emphasizing specialty pharmacy expansion, home health acquisitions, technology investments and opportunities to integrate services for comple
Cottage Health Hosts Sepsis Conference Focused on Early Recognition and Treatment
Cottage Health brought together physicians, nurses, pharmacists, respiratory care practitioners and other clinicians from across the region on Friday,
Health Brief: The business of treating Alzheimer’s
Plus: FDA takes aim at a major compounding pharmacy’s GLP-1 offerings
Health Brief: The business of treating Alzheimer’s
Plus: FDA takes aim at a major compounding pharmacy’s GLP-1 offerings
Meet the new faculty in the College of Pharmacy and Health Sciences
Let’s find out more about the new nursing lecturer in the Henry P. Becton School of Nursing and Allied Health!
Meet the new faculty in the College of Pharmacy and Health Sciences
Let’s find out more about the new nursing lecturer in the Henry P. Becton School of Nursing and Allied Health!
Pioneer of China NewCo model sued in US over trade secret misuse, double-dealing
A legal feud unfolding in New York is putting a spotlight on the work of a business development veteran who is credited for pioneering one of biopharma’s hottest dealmaking mechanism: the China “NewCo” model. In a lawsuit originally filed in New York state court and recently moved to federal court, China’s Lepu Medical Technology has alleged that biopharma business development consultant Su Zhang, who was hired to help shop its GLP-1 weight-loss candidates to Western partners, engaged in corporate double-dealing and trade secret leaks. According to the complaint, while acting as Lepu’s primary dealmaking liaison for a group of obesity and metabolic disease drug candidates, Zhang was secretly double-dipping as the acting chief business officer for a direct competitor, BrightGene Pharmaceutical. “She never adequately disclosed the role, never sought Lepu’s consent, and never proposed any safeguard,” Lepu alleged in its complaint, which was filed in July after Zhang’s consulting firm, CoDevCo, sought certain transaction-based success fees from its angry customer through an arbitration process in Singapore. Lepu, the parent company of Lepu Biopharma, has asked Zhang to pay back its $500,000 retainer and disgorge all benefits she received during the alleged breaches of fiduciary duty, plus other damages and relief. The company has also requested the court grant injunctions to protect Lepu’s trade secrets. The ill-fated partnership officially kicked off in December 2024, when Lepu tapped CoDevCo as its “exclusive business development mechanism” to identify collaborators for the company’s drug candidates. According to Lepu’s complaint, Zhang personally negotiated and signed the agreement as managing director for CoDevCo, which used her home address. Before the Lepu deal, Zhang made a name following a short stint as the global head of business development for Hengrui Pharmaceuticals. It was during her tenure that Hengrui signed a landmark deal granting exclusive rights for a portfolio of GLP-1 assets to Hercules, which was at that time newly established by a group of private equity and venture capital firms. In addition to the regular upfront and milestone payments, Hengrui also gained an equity stake in Hercules, which later became Kailera Therapeutics. The Hengrui-Hercules deal opened a new paradigm, where a Chinese biopharma company spins off certain early-stage assets to investors for further development through the creation of a new company abroad. The “NewCo” model quickly came into vogue as it allows Western investors to access high-potential assets originating from China at an early stage while giving the Chinese licensors an opportunity to reap long-term benefits through equity stakes in the new firms. The NewCo model proved its value when Kailera staged a record-breaking $625 million IPO on Nasdaq this April, merely two years into the Hengrui deal. Related Kailera CEO 'knew we were in a good spot' before obesity biotech's record-breaking $625M IPO On her LinkedIn page, Zhang described her work at Hengrui as “[b]uilding team and capability from the ground up,” forming NewCo and major pharma partnerships worth billions of dollars. Lepu clearly wanted that kind of track record to help boost its own cardiometabolic portfolio, which includes a range of assets for obesity, Type 2 diabetes, fatty liver disease and muscle preservation during weight loss treatment. “Lepu’s pipeline is very valuable, but only if Lepu could secure the right international partner to expand into the overseas market during the available commercial window,” the company argued in its complaint. The Chinese biotech said it had little knowledge of U.S. laws, customs or business practices in the business development field, and therefore “needed to rely entirely” on the expertise of Zhang and her team as the firm’s first engagement of a U.S.-based BD consultant. “Zhang’s dominating influence on the business development strategy is further evidenced by the fact that she personally controlled the business-development communications on behalf of Lepu with potential partners,” Lepu said in its complaint. After entering the deal, Zhang introduced Lepu to her four associates. According to Lepu’s version of events, all of them were allegedly employed at different time points to perform similar jobs at other Chinese companies that Lepu described as its competitors, while having access to Lepu’s confidential information. As such, Lepu described Zhang’s team as “a roster of individuals whose primary professional loyalty, by virtue of their concurrent full-time employment, ran to Lepu’s competitors.” As well as the specific examples set out in the case, a look at Lepu’s deals over the period suggests Zhang may have been involved in at least one transaction. During their partnership, Lepu, through its subsidiary Shanghai Minwei Biotechnology, also out-licensed its GLP-1/GIP/FGF21 agonist MWN105 to a NewCo called Sidera Bio in the fall of 2025. The deal included an upfront and near-term payment of $35 million, up to $1.01 billion in milestones, and a 9.99% stake in the Danish startup. It seems likely that Zhang facilitated the Minwei deal given that Lepu is on record as having used CoDevCo as its “exclusive business development mechanism.” The big shock for Lepu came in the form of a news article on June 25, 2025. The article, reporting on phase 2 data for BrightGene’s GLP-1/GIP receptor agonist BGM0504, identified Zhang as acting chief business officer of the Lepu rival. Blindsided by her association with BrightGene, Lepu confronted Zhang in July 2025. “Lepu was given assurances that there was nothing to be concerned about and told that Zhang would explain the matter to Lepu,” Lepu alleged in its complaint. “Zhang never did.” Lepu claimed that Zhang had the motive and opportunity to steer potential prospective partners toward BrightGene or other competitors. Later, in February 2026, one of Zhang’s associates joined BrightGene as the vice president for global business development, according to the complaint. Around the same time, Lepu sent written demand letters asking Zhang to account for her BrightGene role, identify what confidential data were shared with the rival firm, and provide any conflict-of-interest or firewall policies during the engagement. According to Lepu, neither CoDevCo nor Zhang answered the questions in their responses. Related Novo vs. KBP: How a $1.3B deal turned into a fraud accusation and an international legal fight In a motion to dismiss filed with the U.S. District Court in the Eastern District of New York on Sept. 4, Zhang’s legal team argued that Lepu’s agreement was signed with CoDevCo, and that an employee of the contractor does not owe fiduciary duties to the client. In its complaint, Lepu said: “That CoDevCo was the contracting entity does not insulate Zhang from personal liability for duties she personally undertook and personally breached.” Taking the argument one step further, the defending party argued that the consulting agreement “does not create a fiduciary relationship even between CoDevCo and Lepu; instead, it identifies CoDevCo as an independent contractor retained to market Lepu’s business to potential western partners.” Although CoDevCo was Lepu’s exclusive business-development contractor, there were no terms stipulating that the consulting firm should serve only Lepu, Zhang’s lawyer noted. As to Lepu’s claims that Zhang misappropriated trade secrets, the defendant argued that Lepu authorized the use of the information so Zhang’s team could perform their service per the agreement. In a rebuttal filed on Sept. 11, Lepu’s lawyer set out why they believe the Chinese biotech satisfied New York law’s misappropriation definition by alleging that the defendant used a trade secret “in breach of a duty or through improper means.” As an alternative to dismissing the suit, the defendant suggested the action should be stayed pending outcomes from the arbitration of a separate case in Singapore. While NewCo pioneer Zhang is defending her business arrangements, momentum behind the NewCo trend has continued unabated into 2026. Through August, Chinese biotech assets have spurred 15 NewCo deals this year, according to local trade publication PharmaDJ.
Intense Media Pressure an Emerging Challenge in CHO Business
Growing culture media requirements are becoming a major logistical and storage challenge for biopharmaceutical manufacturers.
Oracle Adds Domain-Trained AI to Life Sciences Data Intelligence Platform
Natural-language, domain-aware AI capabilities and expanded analytics tools enable pharmaceutical research teams to explore real-world data and generate traceable, decision-ready evidence ORLANDO, Fla., Sept. 24, 2026 — Oracle Life Sciences Data Intelligence now combines real-world data, domain-trained AI capabilities, and advanced analytics in a single connected intelligence platform, helping pharmaceutical research teams move from questions […]
As pharmacies across Vermont close, North Star Health opens 3 new ones
SPRINGFIELD — In the era of independent pharmacy closures and ballooning drug costs, a new pharmacy that charges less for drugs seems counterintuitive, if not impossible. But that’s exactly what North Star Health, a Federally Qualified Health Center that operates medical clinics in Vermont and New Hampshire, did when it officially launched three new pharmacies […]
Kevin Byram named Medical Director of the Vanderbilt Specialty Pharmacy
Kevin Byram, MD, Associate Professor of Medicine, has been named Medical Director of the Vanderbilt Specialty Pharmacy, effective Oct. 1.
Family-run pharmacy in Melbourne Beach closes retail side. Gallery
Savers Pharmacy, on Ocean Drive in Melbourne Beach, opened in 1983. It's shutting down its retail side but will continue to serve people in long-term care.
As pharmacies across Vermont close, North Star Health opens 3 new ones
The pharmacies take advantage of the health center’s federal designation that allows them to pay less for drugs, charge patients lower costs and still meet their bottom line.
Branded Pharmaceuticals Stocks Q2 In Review: Phibro Animal Health (NASDAQ:PAHC) Vs Peers
Let’s dig into the relative performance of Phibro Animal Health (NASDAQ:PAHC) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnin...
Pete Buttigieg Slams ‘Corruption’ in US Politics: ‘Corporate Money Is Flooding the Election’ and Big Pharma Will ‘Get Their Way’
Former Transportation Secretary Pete Buttigieg criticized what he described as corruption in U.S. politics, arguing that corporate money and political incentives have left Americans without a system t...
Merck Life Science Expands Bengaluru Manufacturing with €13 Million Investment
Merck Life Science is expanding its manufacturing capabilities in Bengaluru with an investment of approximately €13 million, strengthening the company’s ability to supply critical materials to customers across India and the wider Asia-Pacific region. The expansion at Merck Life Science’s Jigani site in Bengaluru will introduce biological buffer manufacturing alongside the facility’s established chemistry capabilities. The investment is designed to enable faster and more reliable access to critical materials used by customers across research, diagnostics, biotechnology and biopharmaceutical manufacturing. The development further advances Merck Life Science’s “in-region, for-region” approach, under which the company is expanding manufacturing capabilities closer to the markets and customers it serves. By adding biological buffer production in India, the Jigani expansion will broaden the site’s manufacturing capabilities while strengthening Merck Life Science’s regional supply infrastructure for the rapidly developing life sciences sector across India and Asia-Pacific. The company said the expansion reflects both the contribution of its teams and its collaboration with government and industry stakeholders. Merck Life Science acknowledged the support of India’s Department for Promotion of Industry and Internal Trade (DPIIT), the German Embassy New Delhi, and Invest India in helping strengthen life science manufacturing capabilities in the region. The investment comes as India continues to expand its role across pharmaceutical, biotechnology, diagnostics and biomanufacturing value chains, increasing demand for dependable regional access to materials supporting research and manufacturing operations. The Bengaluru expansion reinforces Merck Life Science’s focus on building manufacturing capacity within Asia-Pacific and supporting customers through a more regionalised supply network.
Hy-Vee pharmacies to provide drive-thru flu vaccine clinics
Hy-Vee Pharmacy locations will offer drive-thru flu vaccine clinics from 4 to 6 p.m. today and Sept. 29, the grocer announced. No appointment or prescription is required. Hy-Vee pharmacies offer regular- and high-dose flu vaccines, which are free with Medicare and most insurance plans. Flu shots are available without a prescription to eligible patients 6…
Earth Science Tech’s (ETST) Uplist to OTCQB Venture Market Continues Series of Milestones in Fiscal 2027
Austin, Texas, September 22nd, 2026, FinanceWireEarth Science Tech (OTCQB: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, successfully uplisted to the OTCQB Venture Market effective September 17, 2026. The listing on OTCQB, an established public market for…
Albany College of Pharmacy and Health Sciences Data Breach Settlement
Albany College of Pharmacy and Health Sciences in New York State has agreed to settle a class action lawsuit stemming from a 2024 cybersecurity incident Albany College of Pharmacy and Health Sciences has agreed to settle a class action lawsuit related to a 2024 cybersecurity incident that affected 26,411 individuals.
Jaguar Health Receives Fee Waivers from FDA
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027SAN FRANCISCO, CA / ACCESS Newswire / September 22, 2026 / (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the U. Food and Drug Administration (FDA) has granted Napo's request for a waiver of the fee associated with the Pres
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
Supports Optimi’s planned Phase 2 psilocybin trial in major depressive disorder and Phase 3 MDMA trial in PTSDVANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the appointment of Michael Blough, Ph.D., as Chief Clinical Development Officer. Dr. Blough has significant experience leading Health Ca
Avondale health center is getting a major upgrade
The renovation will bring medical, pharmacy and dental services under one roof.
Craven County Community Health Center cuts ribbon on Havelock expansion, adds VA clinic and pharmacy
Craven County officials celebrated the opening of an expanded community health clinic Monday, bringing essential medical, pharmacy, and behavioral health care closer to home for eastern county residents.
Hanx Biopharmaceuticals (Wuhan) Enters Agreement To Explore AI For Science In Drug Research
Hanx Biopharmaceuticals (Wuhan) Co Ltd HKEX:3378:
Transformative Biological and Environmental Frontiers: Synthesizing the 2026 Tang Prize Science Laureates
The Tang Prize in Sustainable Development and Biopharmaceutical Science honors pivotal scientific advances that improve global health, restore damaged ecosystems, and deliver transformative medical treatments. The 2026 science laureates, Professor Susan Solomon for Sustainable Development, along with Dr. Steven A. Rosenberg, Dr. Michel Sadelain, and Dr. Carl H. June for Biopharmaceutical Science, demonstrate how disciplined
Czech PM targets medicine prices in new bid to cut healthcare costs
The pharmaceutical industry warns that medicines already account for a declining share of healthcare spending, arguing that efficiency gains should also be sought in other areas
LVHN Health Care Partner of the Month
Elissa Remmel Job: PharmD, Pharmacy Supervisor Education/Training: Elissa Remmel earned her Doctor of Pharmacy at the University of the Sciences, Philadelphia. Service line or specialty: Lehigh Valle...
Heavy caffeine users and deeper sleep; wonders of microscopic life; preparing for life after an Alzheimer’s diagnosis; plus other stories with Vanderbilt Health sources
Beth Malow, MD, Professor of Neurology and Pediatrics in the Vanderbilt Sleep Division, was quoted in Women’s Health about a surprising study from the Journal of Psychopharmacology indicating that heavy caffeine users get deeper non-rapid-eye-movement sleep, even while sleeping less time. The New York Times quoted Dylan Burnette, PhD, Associate Professor of Cell and Developmental Biology, in a story (with videos) about the wonders of the microscopic life all around us. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: Prevention (rabies vaccinations); Healthline (update on the Cyclospora outbreak); Prevention again (hundreds now sickened in measles outbreak); and AARP (“How do we know vaccines are safe?” video interview and transcript). Science posted a story about a new NIH research center on vaccine harms. The piece quotes Kathryn Edwards, MD, Professor of Pediatrics, Emerita. Lealani Mae Acosta, MD, MPH, Associate Professor of Neurology, was quoted in an Everyday Health story about how a person, after a diagnosis of Alzheimer’s disease, can enrich their life and prepare for the future. Amalia Peterson, MD, Assistant Professor of Neurology, was quoted by Everyday Health in a piece about common medications linked to lower dementia risk.
FL health department proposes allowing pharmacists to administer chikungunya vaccine
In Florida, there have been 189 reported cases of chikungunya disease so far this year, according to DOH’s reportable diseases frequency report. Most were reported in Miami-Dade.
MU Health Care earns national recognition by SNMMI
(9/18/26) MU Health Care has been designated a Clinical Radiopharmaceutical Therapy Center of Excellence by the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Expanded Havelock health center adds exam rooms, pharmacy and VA behavioral clinic space
HAVELOCK, Craven County — Craven County leaders will cut the ribbon Monday on an expansion of the Craven County Community Health Center in Havelock.The ceremony
Florida health department moves to allow pharmacists to give chikungunya vaccine
A proposed rule would allow people to receive the shot at pharmacies. The Board of Pharmacy is accepting public comments through Oct. 8.
Walmart launches rural health ambassador pilot, tapping pharmacists for expanded support
Big box retailer Walmart is launching a six-month pilot program that places pharmacists in a new “Health Ambassador” role at five rural stores to help customers navigate health and wellness resourc | Walmart’s Health Ambassador Associate roles will be given to trained pharmacists at each store participating in the program.
Testosterone scripts for women rise, along with denials and delays
Women increasingly turning to testosterone therapy to manage menopause symptoms are running into unexpected prescription delays and denials at pharmacies, according to interviews with more than half a dozen doctors, nurses and patients.
England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal
A breast cancer drug from AstraZeneca will now be available in England after a pricing deal was reached, in part a result of the U.S.-U.K. pharma pact.
SCAN Health Plan, Walmart partner on Medicare Advantage plans
SCAN Health Plan is partnering with retail giant Walmart to launch a co-branded Medicare Advantage plan in two states, the companies
A health-and-wellness company begins trading on a different public market Sept. 17
OTCQB companies undergo annual verification and management certification; Earth Science Tech combines pharmacy operations, telemedicine and direct fulfillment.
From PA charter student named Doctor of Medical Science program director
Campbell University’s College of Pharmacy & Health Sciences has named Ashley Nordan, DMSc, MHPE, MSCR, PA-C, program director of its… More on this post
Ennature Biopharma Advances Women’s Health Science With Fast-Acting Shatavari and Sustained-Release Ginger
NOIDA, India, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Ennature Biopharma is expanding the clinical evidence for its Aspargize and Gingeren botanical ...
Syneos Health and Tufts CSDD Study Shows Clinical Trial Performance Depends More on Operating Model Design Than Sourcing Strategy
Data From 13 Leading Pharmaceutical Companies Points to Execution, Governance and Partner Coordination as Key Drivers of Trial PerformanceMORRISVILLE, N.C., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, today announced findings from a first-of-its-kind benchmarking study conducted by the Tufts Center for the Study of Drug Development. The research examined one of the industry’s most persistent questions: does the sourcing
Ennature Biopharma Advances Women’s Health Science With Fast-Acting Shatavari and Sustained-Release Ginger
NOIDA, India, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Ennature Biopharma is expanding the clinical evidence for its Aspargize and Gingeren botanical ingredients, addressing two distinct areas of women’s health: menopause and menstrual health. The botanical formulations pair Shatavari for menopausal support with sustained-release ginger for menstrual comfort. The findings come amid growing interest in evidence-based women’s health solutions and ahead of World Menopause Month and SupplySide Global in O
Walmart to test health ambassador program in rural stores
Walmart continues to find ways to build and expand its healthcare business. The efforts, which include store pharmacists, telehealth options for Walmart+ members, now include testing a health ambassador role...
Walmart to test health ambassador program in rural stores
Walmart continues to find ways to build and expand its healthcare business. The efforts, which include store pharmacists, telehealth options for Walmart+ members, now include testing a health ambassador role...
DHL inks health care logistics deals in South America
Parcel giants have been investing in health care and pharmaceutical shipping, among their most lucrative lines of business.
Three UConn School of Pharmacy Alumni will be recognized at the 2026 UConn School of Pharmacy & Pharmaceutical Sciences Alumni Awards
The 2026 UConn School of Pharmacy & Pharmaceutical Sciences Alumni Awards take place on Saturday, September 19, where three alumni will be recognized fo ...
Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
7 million contracted units added in under two weeks \- Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million today * Secured orders for 1.
RxLogic and Epidaurus Health Bring Automated Prior Authorization Live on an Independent Adjudication Platform
NASHVILLE, Tenn. and ALEXANDRIA, Va., Sept. 15, 2026 (GLOBE NEWSWIRE) -- RxLogic, a leading technology company that performs fully compliant pharmacy benefit operations with easy, rapid implementations, and Epidaurus Health, an AI software company focused on prior authorization (PA) automation, today announces that the Epidaurus PA platform is live in production on RxLogic's adjudication rail, serving a shared pharmacy benefit manager client. AI-driven prior authorization now runs directly on Rx
AbbVie named Official Pharmaceutical Sponsor of PGA TOUR, 2026 Presidents Cup; launches Birdies for Brain Health campaign
NORTH CHICAGO, Ill.– AbbVie (NYSE: ABBV), a global pharmaceutical leader, and the PGA TOUR announced Tuesday a partnership naming AbbVie the Official Pharmaceut
Novo Nordisk (CPSE:NOVO B) Rebrands As Novo In Consumer Health Push
Novo Nordisk (CPSE:NOVO B) has rebranded to "Novo" as part of a shift toward a more consumer-focused healthcare identity. The group is introducing a new corporate culture intended to support its obesity and diabetes franchises in increasingly crowded markets. Management positions the rebrand as a move beyond traditional pharmaceuticals, with a broader focus on consumer-facing health solutions. The shift to the Novo identity reworks how the business presents itself to obesity drug users and...
‘A financial lifeline’: Rural pharmacists hope federal funds can bridge healthcare gaps
CINCINNATI (The Ohio Newsroom) -- A large federal grant could help better connect rural pharmacies with local physicians.The Ohio Department of Health recently announced that $2 million from the T
Provost announces leadership appointments, promotions
Eric Barker has been named senior vice president for health affairs and Preeti Sivasankar as interim dean of the College of Pharmacy, two appointments taking effect Oct. 1. Cherise Hall is now senior vice provost for enrollment and student strategy, a promotion that took effect July 1.
BioMarin appoints Robert Plenge to its Board and Science & Technology Committee
BioMarin appointed Robert Plenge, M.D., Ph.D., to its Board of Directors and to the Science and Technology Committee, effective September 10, 2026.Original SEC Filing: BIOMARIN PHARMACEUTICAL INC [ BMRN ] - 8-K - Sep. 14, 2026This is an AI-powered summary. It may contain inaccuracies. Consider veri…
Precision for All: Closing the Gap Between Science and Life
Biopharma innovation is moving fast, yet according to Ryan Keeling, CEO of Diaceutics, the industry continues to face a fundamental challenge: too many eligible patients never reach the therap | Why are so many eligible patients still missing the therapies designed for them?
What supplement formulators can borrow from pharmaceutical delivery science
Poor absorption is a problem the pharmaceutical industry solved decades before most supplement formulators had to think about it. Compounds that show real biological activity in a lab often perform far worse once they're inside the body, because getting a molecule to dissolve, cross the gut wall and reach circulation is a separate engineering problem from proving the molecule does something useful
‘A financial lifeline’: Rural pharmacists hope federal funds can bridge healthcare gaps
The Ohio Pharmacy Association received millions of dollars to increase connectivity between rural pharmacists and other healthcare providers.
‘A financial lifeline’: Rural pharmacists hope federal funds can bridge healthcare gaps
The Ohio Pharmacy Association received millions of dollars to increase connectivity between rural pharmacists and other healthcare providers.
Özgür Tuncer: Health and vaccine equity
Cold-chain dependence is not just a logistical burden, it is a primary driver of global health inequality. Following promising Phase 1 results for SPVX02, StablePharma’s chief executive discusses how thermostabilisation technology can redefine global health equity.
CPHS Prospective Student Day offers firsthand look at health sciences programs
Campbell University’s College of Pharmacy & Health Sciences welcomed prospective Doctor of Pharmacy, Doctor of Physical Therapy and Physician Assistant… More on this post
GE HealthCare in talks over possible $1 billion deal for Sofie Biosciences, FT reports
GE HealthCare Technologies is in talks over a possible $1 billion deal to buy radiopharmaceutical developer Sofie Biosciences, the Financial Times reported on Sunday citing people familiar with the matter.
Wilmington health tech founder launches new venture
Several years after launching his health tech startup Artemis Immersive, founder Adam Isley is setting his sights on new horizons. Co-founded in 2023 by husband-and-wife Adam Isley and Kaylan Barbrey, along with Matthew Raffa and Bill Blakesley, Artemis Immersive began as a spatial medtech company that created digital renderings of medical scans for viewing in augmented reality (AR). Isley said the firm, which won an NC Tech award in the Biotech + HealthTech Innovation category last year, has raised $1.2 million in total in seed funding since launching. Isley has since created a new venture, Research and Me, building on the Artemis platform. Like Artemis Immersive’s core software, VoxScan, Research and Me combines health data with artificial intelligence in a 3D interactive environment to help patients better understand health outcomes and provide integrative wellness support. While the Artemis product is no longer Isley’s primary focus, he said the company’s technology and ambitions have evolved into different ventures, like Research and Me. "It's a different venture building on the Artemis platform, and there'll probably be more,” Isley said. He added, "I was very disappointed in the quality of the information available to general patients about their healthcare... I wanted to give patients more and a better plate of choices." Research and Me is still in its beta phase, Isley said, with usability testing ongoing in partnership with the firm’s partner, Medicap Pharmacy and Wellness Center, owned by Barbrey. "As someone who's kind of dedicated their life to working in healthcare, I've tried to bring this spirit and passion to it,” he said, “and a lot of the resources that we'll be providing are free — like a base level of free care for any patients, or medical education if they've got specific conditions." Isley describes Research and Me as a “patient-first” platform designed to securely store and pseudonymize health data and use AI and medical literature to generate insights. The insights are presented in an interactive 3D environment for patients and providers to explore conditions, treatments and wellness plans together. "It's almost like a democratization of understanding medical information," Isley said. "We take a whole bunch of clinical data, we take a whole bunch of peer‑reviewed, published studies on PubMed, and we try to turn them into chunks of information that normal humans can understand." Like VoxScan, the Research and Me platform lets users interact with 3D anatomical models for visualization. The platform provides a space for tracking, notes and insights. The platform also supports video conferencing, Isley said, allowing providers or coaches to examine models and data together. "We wanted to create a safe environment where you can start to learn and experiment with new features about your health, using agents to do that,” Isley said. While Research and Me is in beta-phase testing with Medicap Pharmacy, Isley said he envisions the platform serving a wellness-oriented community, working with sports performance clinics and hormone optimization. Isley, who is working towards a wellness-coach board certification, also plans to offer functional wellness consults through the platform. Long‑term, Isley says he wants the platform to embody an “integrative health practitioner” approach, “connecting experts of different fields and specializations in a way that they can make a greater impact in people's lives.” “For people in the state of North Carolina, it's already a win,” Isley said of the Medicap rollout, noting that partner clinics get “immediate resources for learning about their health and wellness conditions… out of the box.” Isley plans to launch Research and Me’s provider portal in 2028 and begin pursuing integrations with larger systems, he said.
Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units
* 500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana Laboratories * Expands Cosmos Health's manufacturing presence in cardiovascular pharmaceuticals, adding production of statin-based lipid-lowering therapies to Cana's growing contract manufacturing portfolio * Cumulative contract manufacturing orderbook increases to more than 27.
Your next prescription could be treating a side effect from the last one
A major Ontario study found 24 common medication chains in which one drug’s side effects can be mistaken for a new medical problem, leading to another prescription. Researchers say closer medication reviews, pharmacist involvement, and automated alerts could help prevent these potentially harmful prescribing cascades.
The Week in Health:Mexico Health Summit, Pharma Investment, Funds
MHS 2026 spotlights digital health, chronic disease, and affordability, as pharma investment grows and COFEPRIS advances regulatory reform.
RWJBARNABAS HEALTH NAMES DR. DAVID SILVERMAN SENIOR VICE PRESIDENT AND CHIEF PHARMACY OFFICER
RWJBarnabas Health, the largest, most comprehensive academic health system in New Jersey, has appointed David Silverman, PharmD, BCPS, BCCCP as Senior Vice President and Chief Pharmacy Officer, effective September 14, 2026.
What Health Equity Champions Can Learn from Pharmaceutical Sales
The same mechanics can now help people meet new Medicaid work requirements or exemptions, increase referrals to evidence-based health interventions, and dramatically increase enrollment in vital programs that improve health outcomes and reduce inequities.
Lilly’s GLP-1 Windfall to Fund Investments in Women’s Health
The pharmaceutical giant has been assembling experts and hunting for new medicines across conditions including bone health and endometriosis, sources told Bloomberg.
The Escalator: Inizio, Health Catalyst, Eversana and more
See which leaders are on the move across the pharma, biotech and medical marketing industries.
FAMU College of Pharmacy gives free health screenings and vaccines during 75th anniversary event
Florida A&M University’s pharmacy gave out free health screenings and vaccines Wednesday as part of a weeklong 75th anniversary celebration.
Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets
Watch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach patients is changing—and leading to debates over pricing and coverage. Learn how your company can be both patient-forward while also maximizing revenue in this unique environment.
Luma locks down 15-year, $410M fund for life science investments
Luma Group today announced the final close of its inaugural life sciences venture capital fund, totaling $410 million. The New York-based investment firm has had a grip on life sciences since its founding in 2023. The funds unveiled today, dubbed LumaBio Fund I, include investments that have already been made into more than 10 biotechs. They include the likes of eye disease-focused Character Biosciences, rebranded Belgian biotech Coultreon Biopharma and cellular rejuvenation company Altos Labs. The fund saw early success when one of the companies it co-founded, called Vaccine Company, was picked up by Eli Lilly earlier this year for up to $1.55 billion. The acquisition of the in vivo nanoparticle technology-focused biotech formed part of a trio of vaccine buys for the Big Pharma, which has itself been on a prolonged spending spree in 2026. Luma's fund is structured as a 15-year investment with plans to support groundbreaking science and support companies through key milestones from discovery to commercialization, Luma explained in the release. "We founded Luma Group on the belief that extraordinary science, supported by patient, long-term capital, has the power to improve millions of lives," Joshua Fink, founder and managing member of Luma Group, said in the release. "This fund represents more than capital—it is a commitment to partnering with extraordinary innovators as they translate visionary science into life-changing medicines."
Clearway Health Scales Operational Excellence with Appointment of Chief Operating Officer
/PRNewswire/ -- Clearway Health, a company that partners with hospitals and health systems to plan, build and operate specialty pharmacy programs, announces...
Aurora Appoints Seasoned Biopharmaceutical Executive to Lead Commercial Acceleration of Global Medical Cannabis Business
/PRNewswire/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Faris El Refaie, a...
Springfield Health Department partners with Big Y for free vaccine clinics
The Springfield Department of Health and Human Services and Big Y Pharmacy have partnered this season to offer vaccine clinics for community members.
Scientists and algorithms: Finding the right balance in modern drug development
The future of drug development is not scientists versus algorithms. It is scientists and algorithms working together.
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
With a detailed data drop that AstraZeneca’s R&D chief described as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become a flagship biologic in chronic obstructive pulmonary disease (COPD). In detailed results from the late-stage Oberon and Titania trials—first teased in March and detailed in full at the European Respiratory Society Congress in Barcelona this week—the drugmaker laid out the extent of its IL-33 inhibitor’s potential to reduce moderate and severe exacerbations in a wide range of COPD patients still struggling with those “lung attacks,” as AstraZeneca’s Sharon Barr, Ph.D., called them, despite using standard-care inhaled therapy. In the headline results, a 300 mg dose of tozorakimab given once every four weeks curbed those moderate and severe exacerbations in the studies’ primary population of former smokers by 29% in the Oberon study and 34% in Titania. In the overall population of both current and former smokers, these reductions were 30% and 29%, respectively, versus placebo and inhaled standard of care. The benefits also extended to clinically meaningful exacerbation reductions in all prespecified patient subgroups and specifically turned up promising signals in patients across a range of blood eosinophil counts, with Barr telling Fierce that “it’s the details that make this even more exciting than the high-level results that we’ve already shared.” In fact, during AZ’s tozorakimab poster presentation at the ERS 2026 Congress this past weekend, attendees were so enamored by the data that event organizers had to encourage people to clear the room and look at the other presentations on offer, Barr said in an interview. “I think it really speaks to the fact that there is a lot of buzz around these data because the entire respiratory community has been so desperate for new therapies for these patients,” she explained. The respiratory disease continues to represent a “staggering unmet medical need,” Barr said, highlighting the COPD exacerbations that the Oberon and Titania studies homed in on, which she added carry a greater mortality risk than a heart attack. “When a patient has a severe exacerbation, only about half of them are still alive within three and a half years,” she pointed out. As for tozorakimab specifically, Barr christened the molecule “an AstraZeneca science success story,” harkening several years back to the point at which researchers began to explore IL-33 as a driver of respiratory disease, and COPD in particular. At the same time, “there was still so much that wasn’t understood,” she admitted, highlighting the insight that IL-33 signals through both ST2 and EGFR through the RAGE pathway, a discovery Barr attributed to AstraZeneca's own scientists. Understanding the need to tackle both pathways in COPD—and aware of competitor candidates in the hopper, including one that bound ST2—the company ultimately had to make some “courageous decisions,” Barr said. These included taking a prior COPD molecule offline and going back to the drawing board to reinvent its potential IL-33 label “to make sure that we had a molecule that could block signaling through both arms of the pathway, through both the reduced form and the oxidized form, knowing that we wouldn’t be first, but striving to be best.” “When we put [tozorakimab] into the clinic, we firmly believed that we had a differentiated molecule, and we saw the other molecules blocking just ST2 or partially blocking IL-33, unable to deliver two positive pivotal studies in COPD,” Barr explained. “We kept marching forward because we believed our molecule was differentiated, and now I think we have the clinical validation that supports that.” Ultimately, AstraZeneca finds itself on much better footing these days when it comes to potential biologic rivals to tozorakimab in COPD. Sanofi and Regeneron’s Dupixent, for instance, is approved to treat COPD exacerbations in patients with high eosinophil counts, but not low ones. Meanwhile, the future has become cloudier for other next-gen IL-33 candidates from Sanofi and Regeneron, as well as Roche, which have suffered trial flops in recent years. One other potential ingredient for AstraZeneca’s success in its duo of studies was that the company was “ambitious in the trial design, willing to look at an all-comers population,” Barr said, “and willing to enroll the most severe patients.” Prior studies for would-be biologics rivals in COPD “avoided enrolling” those patients, she pointed out. She also highlighted the Big Pharma’s painstaking design of exacerbations in its trial, which “gave us a very rigorous readout,” and pointed to “the extra effort and investment” the company put in to understand the effect of mucus plugs in patients. Barr described mucus production as a “key feature in disease diversity,” noting that mucus plugs—obstructing clumps of mucus that block patients’ airways—are associated with worse outcomes in COPD. In its data announcement, AstraZeneca noted that an integrated analysis of Oberon and Titania found tozorakimab “demonstrated a reduction in patients’ mucus plug score,” with the pharma claiming its biologic is the first to deliver such results in a broad COPD population. “So being able to reduce those mucus plugs, we expect, is an important part of driving benefit for patients who are living with COPD,” Barr said. Again touching on the breadth of the study populations, Barr added that tozorakimab “worked across all eosinophil levels in both current and former smokers across all levels of lung function,” which she suggested “really simplifies decision-making for clinicians, and it allows them to offer therapy to the broadest possible patient population.” In the highest patient eosinophil count group, tozorakimab helped chart a 43% reduction in exacerbation risk, which Barr stressed were “unprecedented data.” In the mid-level group, AZ’s drug delivered a 23% reduction and, in the lowest group, a 34% reduction in eosinophils, which Barr said suggests efficacy “in all patient subgroups.” As for AZ’s recent guidance upgrade on the medicine’s sales opportunity, the lift from a $3 billion to $5 billion range to $5 billion plus was informed by multiple factors, Barr said, including the fact that “in 2024, there were multiple competitors, and there aren’t anymore.” Additionally, “we know that this is a massive unmet medical need, and this is a really incredible set of data that we think will be very convincing to the clinical community,” Barr said. Looking ahead to a potential evolution of the COPD treatment landscape, Barr noted that most patients start treatment in the community with an option like a triple therapy, and for them, having an option like AstraZeneca’s inhaler Breztri will remain a “really important part” of that journey. But of the patients uncontrolled on triple therapy, which Barr described as “about half of them today,” just a “small fraction” are currently eligible for biologic therapy, which she emphasized AstraZeneca is working to change. Understanding that COPD is not a “one-size-fits-all” disease, AstraZeneca is also looking at its antibody drug Tezspire for patients with T2-driven disease, and the company continues to think about new mechanisms for tackling COPD through both systemic and inhaled drugs, Barr said.